drugset / Trial / NCT05702788
Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)
RandomizedParallel-groupDouble-blindTreatment
Summary
This study adopts a randomized, double-blind, placebo parallel control design, and is expected to include 168 eligible patients with severe novel coronavirus pneumonia.
Timeline
- Start
- 2022-09
- Primary completion
- 2024-04-23
- Completion
- 2024-04-23
Outcome
Outcome not reported
Stopped (Business): “Sponsor R\&D Strategy Adjustment”